Cipla Ltd Q2 FY26 – ₹7,589 Crore Revenue, ₹1,351 Crore Profit, and One CEO Exit Later: India’s Respiratory King Breathes Easy While Everyone Else Gasps
1. At a Glance
Cipla’s Q2 FY26 results are out, and the headline reads like a neatly wrapped pharma pill — effective, slightly bitter, and mildly addictive. Revenue hit ₹7,589 crore (up 7.6% YoY), EBITDA stood at ₹1,895 crore with a robust 25% margin, and net profit clocked ₹1,351 crore — up 3.7% YoY despite a heavy ₹2,011 crore NPPA demand hanging like a sword of Damocles over its head.
At ₹1,540 a share and a ₹1.24 lakh crore market cap, the stock trades at a fair-ish 22.9x P/E — not cheap, not extortionate, just that middle-class comfort zone of “thoda premium chalta hai.” ROE stands at 17.8%, ROCE at 22.7%, and the debt is practically a rounding error at ₹438 crore. Dividend yield of 0.84% won’t pay for your Netflix, but it’s the thought that counts.
Cipla is now the #3 player in India’s domestic prescription market and the fastest-growing generic player in North America — all while staying the #1 in respiratory drugs. Their global portfolio of 1,500+ products across 65 therapy areas sounds impressive until you realize that 7500 medical reps are out there daily convincing 85% of India’s doctors to write one more “Rx: Cipla”.
The twist? CEO Umang Vohra just announced he’s stepping down in March 2026. Achin Gupta — the current Global COO — takes the baton in April 2026. Classic succession planning or a strategic game of “tag, you’re it”?
2. Introduction
Cipla — the grand old name that made inhalers cool before startups made “air purifiers” a lifestyle. Founded back in 1935, it’s been fighting everything from tuberculosis to patent wars, long before “Make in India” was a slogan.
The company has always lived by one motto: “If it can be copied legally, we’ll sell it globally.” This audacity built Cipla’s empire — a 47-facility strong, ₹28,000+ crore pharma giant that supplies medicines to over 80 countries.
Now, while most of us struggle with breath after a short run, Cipla continues to dominate the respiratory space with a 22.2% market share, proudly holding India’s #1 position in that therapy area. From inhalers to APIs, they’ve got the range of a medical Amazon.
But the bigger story isn’t just inhalers. Cipla is quietly reinventing itself as a digital, diagnostics, and specialty player. They’re now flirting with genomics, cell & gene therapy, and POC (point-of-care) diagnostics with projects like Cippoint, Neodocs, and Achira. Basically, Cipla’s trying to go from “pharma” to “pharma-tech.”
Still, the pharma game isn’t for the faint-hearted. Between the USFDA mood swings, NPPA pricing caps, and NPAs (non-performing approvals), even the best players need nerves of steel — or at least a good sedative from their own product line.
3. Business Model – WTF Do They Even Do?
Cipla’s business model is like a pharmaceutical thali — a little bit of everything and somehow it all works together.
India (43% of revenue): Their fortress. The company dominates chronic therapies — respiratory, urology, and cardiac. You’ll find Cipla in every doctor’s drawer and every chemist’s counter.
North America (26%): The money printer. Fastest-growing generic player in the region with products like albuterol inhalers that keep both patients and investors breathing easy.
SAGA (South Africa & Sub-Saharan Africa, 14%): The colonial comeback. Cipla Medpro is the third-largest private player here.
Europe & Emerging Markets (13% + 4% others): The wildcard geographies that keep the portfolio balanced and compliance teams employed.
Their portfolio runs across 1,500+ products in 65 therapeutic categories, 200+ APIs, and 47 manufacturing facilities. In other words, if there’s a molecule, Cipla’s probably selling it, inhaling it, or exporting it.
On top of that, Cipla is going big on consumer wellness — brands like Nicotex, Cofsils, Omnigel, and ORS now compete with D2C upstarts and influencer ads. They even sell nicotine gum — so technically, they’re curing your addiction by making you addicted differently.
And to stay future-proof, Cipla is investing in clean energy (AMPIN Energy, CleanMax Auriga) and biologics (Kemwell Biopharma JV) — because apparently, curing humanity isn’t enough; they also want to save the planet.
4. Financials Overview
Metric (₹ Cr)
Latest Qtr (Q2 FY26)
YoY (Q2 FY25)
Prev Qtr (Q1 FY26)
YoY %
QoQ %
Revenue
7,589
7,051
6,957
7.6%
9.1%
EBITDA
1,895
1,886
1,778
0.5%
6.6%
PAT
1,351
1,305
1,292
3.5%
4.6%
EPS (₹)
16.7
16.1
16.1
3.7%
3.7%
Annualised EPS: ₹16.7 × 4 = ₹66.8 → P/E ≈ 23x
Commentary: Margins are healthy at 25%, revenue growth is steady, and the bottom line is rising. Cipla doesn’t run; it jogs with stamina. Perfectly Indian.
5. Valuation Discussion – Fair Value Range Only
Let’s play valuation Sudoku:
Method 1 – P/E Approach:
Annualised EPS: ₹66.8
Peer group average P/E: ~28x (Sun Pharma ~35x, DRL ~17x, Zydus ~21x) → Fair Value Range = ₹66.8 × (20x–26x) = ₹1,336–₹1,737
Educational Disclaimer: This valuation range is for educational purposes only. Don’t sell your kidney for a leveraged bet — Cipla already makes the drugs that’ll treat you after.
6. What’s Cooking – News, Triggers, Drama
The last few months have been classic Cipla — calm on the surface, but busy underneath:
Leadership Change: CEO Umang Vohra to step down on March 31, 2026. Achin Gupta (Global COO) will take charge from April 1. Smooth transition or April Fool’s Day testing? You decide.
Tirzepatide Tie-Up: Partnered with Eli Lilly to distribute the blockbuster diabetes and weight-loss drug Tirzepatide under the brand Yurpeak in India. Basically, Cipla just entered the “GLP-1 gold rush.”
USFDA Watch: The Bommasandra facility in Bengaluru got just one observation — a pharma-world equivalent of “A+ but fix your handwriting.”
Acquisitions: Bought 20% in iCaltech (respiratory diagnostics) and 26% in AMPIN Energy C&I Eighteen Pvt Ltd for green power. Because clean lungs and clean energy both sell.
NPPA Whiplash: A ₹2,011 crore demand notice from NPPA — India’s way of saying “you made too much profit, give some back.”
Between new molecules, FDA mood swings, and regulatory surprises, Cipla’s Q2 feels like a season finale — complete with cliffhangers.
7. Balance Sheet
(₹ Cr)
Mar 2023
Mar 2024
Mar 2025
Total Assets
29,300
32,533
37,334
Net Worth (Equity + Reserves)
23,407
26,706
31,194
Borrowings
803
559
438
Other Liabilities
5,089
5,267
5,702
Total Liabilities
29,300
32,533
37,334
Commentary:
Borrowings down to ₹438 Cr — basically pocket change.
